/
Oncology
Advanced Solid Tumor
57
Pipeline Programs↗
50
Active Trials↗
58
Companies Involved↗
Advanced Solid Tumor is a moderately active landscape with 57 programs across 58 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Minghui Pharmaceutical (Hangzhou) Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Qilu Pharmaceutical Co., Ltd.
3 programs
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
3 programs
Minghui Pharmaceutical (Hangzhou) Ltd
2 programs
Abbisko Therapeutics Co, Ltd
2 programs
Betta Pharmaceuticals Co., Ltd.
2 programs
Synnovation Therapeutics, Inc.
2 programs
Pipeline
Programs by Phase
Preclinical6
Phase 127
Phase 224
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
47 of 53 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 53 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.
Analysis
Trial Status
145
clinical trials
Unknown status42 · 29%
Completed39 · 27%
Recruiting35 · 24%
Terminated10 · 7%
Not yet recruiting8 · 6%
Active, not recruiting6 · 4%
Other5 · 3%
Clinical Trials
Trial Activity
145 trials
A Study of EOC237 in Patients With Advanced Solid Tumor
Recruiting·SShanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd·Phase 1·NCT05895825·48 enrolled
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Recruiting·—·Phase 2·NCT05876806·30 enrolled
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT06954558·15 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)